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Background: Radiotherapy of the left breast is associated with higher cardiovascular mortality linked to cardiotoxic
effect of irradiation. Radiotherapy of inner quadrants can be associated with greater heart irradiation, but no study has
evaluated the effect of inner-quadrant irradiation on cardiovascular mortality.
Patients and methods: We identified 1245 women, the majority with breast-conserving surgery, irradiated for
primary node-negative breast cancer from 1980 to 2004 registered at the Geneva Cancer Registry. We compared
breast cancer-specific and cardiovascular mortality between inner-quadrant (n = 393) versus outer-quadrant tumors
(n = 852) by multivariate Cox regression analysis.
Results: After a mean follow-up of 7.7 years, 28 women died of cardiovascular disease and 91 of breast cancer.
Patients with inner-quadrant tumors had a more than doubled risk of cardiovascular mortality compared with patients
with outer-quadrant tumors (adjusted hazard ratio 2.5; 95% confidence interval 1.1–5.4). Risk was particularly
increased in the period with higher boost irradiation. Patients with left-sided breast cancer had no excess of
cardiovascular mortality compared with patients with right-sided tumors.
Conclusions: Radiotherapy of inner-quadrant breast cancer is associated with an important increase of
cardiovascular mortality, a possible result of higher irradiation of the heart. For patients with inner-quadrant tumors, the
heart should be radioprotected.
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introduction
With improving survival rates following breast cancer,
patients are increasingly likely to die of other causes [1]. As
a result, long-term adverse effects of treatment are of major
concern. Cardiovascular disease is particularly important as it
represents the main cause of death among women in
developed countries. Therapies that might increase the risk of
cardiovascular disease can therefore cause more harm than
good. To determine which treatment is optimal, clinicians
need to be aware of long-term risks and benefits of adjuvant
therapies [2].
Several studies have reported that adjuvant radiation therapy
for breast cancer is associated with an increased risk of
cardiovascular mortality [3], probably linked to the
cardiotoxicity of radiation, especially in patients with left-sided
breast cancer where the heart is more exposed to ionizing
irradiation. In an overview of randomized trials, long-term
irradiated breast cancer survivors with left-sided tumors had
a 34% increased risk of death from cardiovascular disease
compared with right-sided tumors [4]. Approximately 50% of
the patients in these studies underwent radiation treatment
before 1975 and had received radiation with techniques today
considered obsolete. Today, with more modern radiation
techniques and generalization of cardiac protection for left-
sided breast cancer, doses to the heart are lower [5]. A
reanalysis of randomized trials after 1975 and recent
observational studies report an important decrease of the excess
cardiovascular mortality linked to radiation of the left breast
[5–9].
In addition to tumor side, tumor locationwithin the breast can
influence heart exposure. The heart probably beingmore exposed
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during radiotherapy of inner-quadrant breast tumors, radiation
of these tumors may be associated with higher cardiovascular
mortality risk as compared with outer-quadrant tumors.
In this study, we aim to evaluate if radiotherapy of inner-
quadrant tumors is associated with an increased cardiovascular
mortality risk. As we wanted to assess the cardiotoxicity of
radiotherapy, we limited the study to lymph node-negative
breast cancer patients for whom other putative cardiotoxic
adjuvant treatments are usually not indicated.
patients and methods
patients
We used data from the Geneva Cancer Registry, which records all
incident cancers occurring in the population of the canton (435 000
inhabitants in 2004). All hospitals, pathology laboratories, and practitioners
are requested to report all cancer cases. Registrars abstract data from
medical and laboratory records. Physicians regularly receive questionnaires
to secure missing data. Recorded data include sociodemographic variables,
tumor characteristics [coded according to the International Classification
of Diseases for Oncology (ICD-O)] [10], stage at diagnosis [coded
according to the tumor–node–metastasis (TNM) Classification of
Malignant Tumors] [11], and treatment received within 6 months after
diagnosis.
The registry regularly assesses survival. The index date refers to the date
of confirmation of diagnosis or the date of hospitalization if it preceded the
diagnosis and was related to the disease. In addition to passive follow-up
(routine examination of death certificates and hospital records), active
follow-up is carried out yearly by linking the files of the Cantonal
Population Office in charge of the registration of the resident population
with the Geneva Cancer Registry database, using personal identification
numbers.
Exact cause of death is established by systematically consulting clinical
records and/or by inquiring of the patient’s physician. The cause of death is
coded according to the International Statistical Classification of diseases
and health-related problems (ICD) established by the World Health
Organization [12].
We considered all patients presenting with a primary, invasive lymph
node-negative breast cancer diagnosed from 1980 to 2004 and who had
received radiation therapy with curative intent. We excluded women with
previous or concomitant invasive cancers (except nonmelanoma skin
cancer) (n = 196), with central (n = 78), overlapping (n = 622), or
unknown (n = 17) quadrant locations. The study finally included 1245
women. Patients were followed up until 30 December 2006.
irradiation techniques
All patients underwent radiation therapy at a single university center. The
whole breast was treated by a classical two-tangential-field technique with
25 fractions of 2 Gy using 6 mV photons. All patients with breast-
conserving surgery received a boost to the tumor bed by an anterior
electron field, usually of 6 or 9 MeV, except for the 100 patients randomly
allocated to the no-boost arm of the 22881 EORTC boost–no boost trial
from 1991 to 1998 [13] and a few patients aged >75 years. Before 1988, the
boost dose was 10 Gy, and then it was increased to 16 Gy. The majority of
patients also had an ipsilateral internal mammary chain (IMC) anterior
field and received 40 Gy in 16 fractions by a mixture of gamma rays and
electrons. After 1990, use of internal chain irradiation importantly
decreased with <15% of patients receiving such radiation with a mixture of
6 mV photons and 9–12 MeV electrons and 46 Gy in 23 fractions; an
oblique anterior field was substituted for the previous anterior one after
2000.
For all breast cancer patients who died of cardiovascular disease, we
consulted the clinical files to collect data on cancer recurrence and type and
dose of radiotherapy.
variables
Variables of interest included age (in continuous), year of diagnosis (in
continuous), tumor differentiation (I, II, III, and unknown), estrogen
receptor (ER) status (positive, negative, and unknown), stage coded
according to the TNM Classification of Malignant Tumors, surgery (breast-
conserving, mastectomy), chemotherapy (yes, no), and hormonal therapy
(yes, no). We considered laterality (right, left) and anatomical breast
locations (outer quadrants ICD-O code: C50.4, C50.5, and C50.6; inner
quadrants: C50.2 and C50.3). Detailed type of surgery was available only
from 1989 and ER status only from 1995.
Cause of death was considered in the following three groups: (i) death
from breast cancer (ICD C50), (ii) death from cardiovascular disease (ICD
I00-I99), and (iii) overall mortality. Additionally, we separately considered
death from cardiac disease (ICD I10-I15, I20-I28, I30-I52) and death from
other vascular diseases (ICD I00-I09, ICD I60-I99).
statistical analysis
Using chi-square test for heterogeneity (for categorical variables) and Fisher
exact t-test (for continuous variables), we compared patient and tumor
characteristics and treatment. We compared cardiovascular, breast cancer-
specific, and overall mortality between patients with left- versus right-sided
breast cancer and with inner-quadrant versus outer-quadrant breast cancer
by log-rank tests and by Cox regressions. To evaluate the independent effect
of breast cancer laterality, we adjusted mortality risk for variables associated
to laterality and cardiovascular disease, breast cancer-specific or overall
mortality, respectively. To asses the effect of breast quadrants on mortality
risks, we adjusted for factors associated to breast quadrants, cardiovascular
disease, breast cancer-specific or overall mortality, respectively. As ER status
and tamoxifen use were highly correlated, we adjusted only for ER status.
In order to examine if the effect of irradiation linked to quadrant on
cardiovascular mortality differed across age group, type of surgery, use of
chemotherapy, use of hormonal therapy, and laterality, we carried out
interaction tests. Interaction terms involved quadrant (inner, outer) and
age group (<50, ‡50), surgery (breast-conserving surgery, mastectomy),
chemotherapy (yes, no), hormonal therapy (yes, no), or laterality (left,
right). We also carried out separate analyses to assess the differences in the
use of internal mammary lymph node chain irradiation and in the dose of
the boost. We considered the following three categories: high level of IMC
irradiation and low boost dose (1980–1987), high-level IMC and high boost
dose (1988–1990), and low IMC and high boost dose (1991–2004).
All tests were two sided and differences were considered statistically
significant at P value <0.05. All analyses were done with SPSS software
(Version 14; SPSS Inc., Chicago, IL).
results
Of 1245 patients, 393 (32%) had tumors in the inner quadrants
and 852 (68%) in the outer quadrants. The mean follow-up was
7.7 years and 155 women died: 28 of cardiovascular disease
including 19 of cardiac disease and nine of other vascular
diseases, 91 of breast cancer, and 36 of other causes.
Age, tumor size, T classification, and use of chemotherapy
were equally distributed between breast laterality and quadrants
(Table 1). The proportion of estrogen-positive tumors was
slightly but significantly higher in the right breast than in the
left (57.3% versus 52.3%; P = 0.031) and hormonal therapy
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was more frequently given for right-sided breast cancer. Also,
the proportion of unknown grade was lower for outer than for
inner quadrants (8.5% versus 15.0%; P = 0.004). The
proportion of inner-quadrant cancers was slightly lower in the
second than in the first period (30.1% versus 39.2%;
P = 0.012). Only few patients had mastectomy. Mastectomy
was more frequently carried out for left- than for right-sided
breast cancer (4.3% versus 2.2%; P = 0.064) and for inner-
quadrant compared with outer-quadrant tumors (5.2% versus
2.5%; P = 0.025).
In univariate Cox analysis, grade, ER status, tumor size, and
use of hormonal therapy were significantly linked to breast
cancer-specific mortality. For cardiovascular mortality,
prognostic factors were age and tumor size (data not shown).
Significant prognostic factors for overall mortality were age,
period, stage, tumor size, and grade (data not shown).
quadrants
Compared with patients with outer-quadrant tumors, patients
with inner-quadrant cancer had worse 10-year overall survival
rates (80.0% versus 87.0%; Plog-rank test 0.009) and breast
cancer-specific survival rates (87.8% versus 90.5%; Plog-rank test
0.096). Cardiovascular mortality rates were higher among inner
quadrants (6.2% versus 1.2%; Plog-rank test 0.002). Patients with
inner-quadrant tumors had a 2.3-fold increased risk of death
from cardiovascular disease [Adjusted hazard ratio (HRadj) 2.5,
95% confidence interval (CI) 1.1–5.4, P = 0.023] (Table 2;
Figure 1). Additional analysis by periods with different
radiation protocols showed that the excess of cardiovascular
mortality was limited to women diagnosed during 1988–2004.
Cardiovascular mortality risk for inner-quadrant tumors was
not increased during 1980–1987 when IMC irradiation was
high and boost dose was low (HRadj 1.1, 95% CI 0.1–9.2). In
contrast, this risk was 11.7 (95% CI 1.1–125) in the period
1988–1990 when IMC irradiation was still in use and the boost
dose increased from 10 to 16 Gy. In the period 1991–2004,
when IMC radiation declined but boost remained high, the
HRadj was 2.6 (95% CI 1.7–7.0) (Table 3).
The risk associated with inner-quadrant tumors was similar
for left- and right-sided breast cancer (Tables 4 and 5) Among
Table 1. Characteristics of irradiated breast cancer patients according to laterality and quadrant
Characteristics Laterality P value Quadrant P value
Right, n (%) Left, n (%) Outer, n (%) Inner, n (%)
Mean age (years) 57.7 57.2 0.439 57.2 57.9 0.320
Mean tumor size (mm) 17.0 17.5 0.301 17.1 17.7 0.258
Year of diagnosis
1980–1990 109 (19.3) 135 (19.9) 155 (18.2) 90 (22.9)
1991–2004 456 (80.7) 544 (80.1) 0.794 697 (81.8) 303 (77.1) 0.052
T classification
T1 433 (76.6) 518 (76.3) 656 (77.0) 296 (75.3)
T2 118 (20.9) 143 (21.1) 178 (20.9) 83 (21.1)
T3–T4 12 (2.1) 15 (2.2) 15 (1.8) 12 (3.1)
Unknown 2 (0.4) 3 (0.4) 0.994 3 (0.4) 2 (0.4) 0.504
Differentiation
I 207 (36.6) 206 (30.3) 294 (34.5) 120 (30.5)
II 204 (36.1) 263 (38.7) 320 (37.6) 147 (37.4)
III 103 (18.2) 130 (19.1) 166 (19.5) 67 (17.0)
Unknown 51 (9.0) 80 (11.8) 0.085 72 (8.5) 59 (15.0) 0.004
ER statusa
Positive 324 (57.3) 355 (52.3) 467 (54.8) 212 (53.9)
Negative 43 (7.6) 80 (11.8) 93 (10.9) 30 (7.6)
Unknown 198 (35.0) 244 (35.9) 0.031 292 (34.3) 151 (38.4) 0.118
Type of surgeryb
Breast conserving 483 (85.5) 562 (82.8) 735 (86.3) 311 (79.1)
Mastectomy 11 (1.9) 25 (3.7) 0.064c 19 (2.2) 17 (4.3)
Unknown 71 (12.6) 92 (13.5) 98 (11.5) 65 (16.6) 0.025c
Chemotherapy
Yes 108 (19.1) 154 (22.7) 185 (21.7) 78 (19.8)
No 457 (80.9) 525 (77.3) 0.125 667 (78.3) 315 (80.2) 0.453
Hormonal therapy
Yes 361 (63.9) 373 (54.9) 515 (60.4) 219 (55.7)
No 204 (36.1) 306 (45.1) 0.001 337 (39.6) 174 (44.3) 0.116
Mean follow-up (years) 7.4 8.0 0.054 7.6 8.0 0.179
aRecorded since 1995.
bRecorded since 1989.
cCalculated chi-square values do not include patients in the category unknown.
ER, estrogen receptor.
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patients who died of cardiovascular disease, irradiated patients
with breast-conserving surgery for inner-quadrant breast cancer
received higher dose to the breast (56.4% versus 48.9% Gy;
P = 0.032) than patients with outer-quadrant tumors and
received boost to the tumor bed more frequently (38% versus
8%; P = 0.18) (Table 6). However, this last result was not
significant. Only few patients received irradiation of the IMC
and we observed no difference according to quadrant site
(Table 3). Local recurrence occurred in only one patient
presenting with right-sided breast cancer of the outer quadrants
and who had received additional surgery and radiation to the
breast.
Finally, patients irradiated for inner-quadrant versus outer-
quadrant breast cancer presented an increased risk of breast
cancer-specific mortality significant in nonadjusted analysis
[Crude hazard ratio (HRcrude) 1.5, 95% CI 1.0–2.3, P = 0.043;
HRadj 1.4, 95% CI 0.9–2.2, P = 0.119] and an increased overall
mortality risk also significant in nonadjusted analysis (HRcrude
1.5, 95% CI 1.1–2.0, P = 0.016; HRadj 1.4, 95% CI 1.0–1.9,
P = 0.063).
laterality
Patients with left-sided breast cancer had similar overall, breast
cancer-specific, and cardiovascular-specific mortality rates as
patients with right-sided breast cancer (Table 2). The HRadj of
women with left- versus right-sided breast cancer was 1.0 (95%
CI 0.7–1.3) for overall mortality, 1.1 (95% CI 0.7–1.7) for
breast cancer-specific mortality, and 0.5 (95% CI 0.2–1.1) for
cardiovascular mortality.
Among patients who died of cardiovascular disease, patients
with breast-conserving surgery for left-sided breast cancer
received a lower dose tumor boost than patients with right-
sided breast cancer (mean dose 11.0 versus 15.7 Gy; P = 0.012)
(Table 6).
Additional analysis considering only mortality from cardiac
disease (19 deaths) instead of overall cardiovascular mortality
confirmed the results presented: the HRadj was 0.7 (95% CI 0.3–
1.6) among women with left- versus right-sided breast cancer)
and 2.7 (95% CI 1.0–6.8, P = 0.041) among women with inner
versus outer quadrant.
None of the interaction tests were significant. With regards
to chemotherapy and type of surgery, too few women
underwent mastectomy or chemotherapy to provide valuable
interaction tests or subgroup analyses. In particular, only 2
of the 30 irradiated women who died of cardiovascular
cancer had received chemotherapy. The results remained
similar when excluding patients with mastectomy or
chemotherapy.
Subgroup analysis showed that the excess of cardiovascular
mortality linked to inner quadrant versus outer was similar
among patients with hormonal therapy (HRadj 2.4, 95% CI 0.9–
6.4) and without (HRadj 2.3, 95% CI 0.6–9.1) and among
patients with left- (HRadj 2.17, 95% CI 0.7–7.3) versus right-
sided breast cancer (HRadj 2.5, 95% CI 0.9–7.2).
Table 2. Number of deaths and crude and adjusted mortality risk (HR) by cause of death according to laterality and quadrant
Laterality P value Quadrant P value
Right (N = 565) Left (N = 679) Outer (N = 852) Inner (N = 393)
Cardiovascular mortality (95% CI)
No. of deaths 16 12 12 16
HRcrude 1 (reference) 0.55 (0.26–1.16) 0.117 1 (reference) 2.64 (1.25–5.60) 0.011
HRadj 1 (reference) 0.52 (0.24–1.12)
a 0.095 1 (reference) 2.46 (1.13–5.37)b 0.023
10-year mortality
cumulative probability
4.5% (2.0–7.0) 1.7% (0.3–3.1) 0.060c 1.2% (0.2–2.2) 6.2% (2.9–9.5) 0.002c
Breast cancer-specific mortality (95% CI)
No. of deaths 37 54 52 39
HRcrude 1 (reference) 1.13 (0.74–1.71) 0.580 1 (reference) 1.54 (1.01–2.33) 0.043
HRadj 1 (reference) 1.12 (0.74–1.71)
d 0.598 1 (reference) 1.40 (0.92–2.15)e 0.119
10-year survival 90.1% (86.6–93.6) 89.2% (86.1–92.3) 0.538c 90.5% (87.8–93.2) 87.8% (83.5–92.1) 0.096c
Overall mortality (95% CI)
No. of deaths 67 88 89 66
HRcrude 1 (reference) 0.98 (0.71–1.35) 0.890 1 (reference) 1.48 (1.08–2.04) 0.016
HRadj 1 (reference) 0.96 (0.69–1.32)
f 0.783 1 (reference) 1.37 (0.98–1.89)g 0.063
10-year survival 83.2% (78.9–87.5) 85.7% (82.2–89.2) 0.577c 87.0% (83.9–90.1) 80.0% (74.7–85.3) 0.009c
aHRs adjusted for all factors linked to cardiovascular mortality or laterality, i.e. age, tumor size, and ER status.
bHRs adjusted for all factors linked to cardiovascular mortality or quadrant, i.e. age, year of diagnosis, tumor size, grade, and type of surgery.
cP value for log-rank test.
dHRs adjusted for all factors linked to breast cancer mortality or laterality, i.e. tumor size, grade, and ER status.
eHRs adjusted for all factors linked to breast cancer mortality or quadrant, i.e. year of diagnosis, tumor size, grade, ER status, and type of surgery.
fHRs adjusted for all factors linked to overall mortality or laterality, i.e. age, year of diagnosis, tumor size, grade, ER status, and type of surgery.
gHRs adjusted for all factors linked to overall mortality or quadrant, i.e. age, year of diagnosis, tumor size, grade, ER status, and type of surgery.
HR, hazard ratio; HRcrude, crude hazard ratio; HRadj, adjusted hazard ratio; CI, confidence interval; ER, estrogen receptor.
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discussion
To our knowledge, this study is the first to report that patients
irradiated for inner-quadrant breast cancer present a more than
twofold increased risk of death from cardiovascular disease as
compared with patients irradiated for outer-quadrant breast
cancer.
Radiation therapy is an important component of the local
management of breast cancer with significant reductions in the
local recurrence, breast cancer mortality risk, and overall
mortality [3, 4]. The increase in death from cardiovascular
disease among irradiated patients could diminish the benefit of
radiation on all survival end points [14]. This could be more
important among patients with lymph node-negative breast
cancer for whom the benefit of radiotherapy is lower in terms
of absolute number of breast cancer deaths [3, 4].
Our results on increased risk of cardiovascular mortality
among patients irradiated for inner-quadrant breast cancer
should be confirmed by other studies. Although patients were
treated in a single institution according to standard protocols,
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Figure 1. Cardiovascular mortalitya among irradiated patients according to tumor location.
Table 3. Risk of cardiovascular mortality by quadrant according to levels
of boost and IMCa
IMC–boost Quadrant Risk (95% CI) P value
Outer Inner
N Deaths N Deaths
High IMC–low
boostb (1980–1987)
72 4 54 2 1.10 (0.13–9.22) 0.928
High IMC–high
boostc (1988–1990)
83 1 33 3 11.67 (1.09–124.5) 0.042
Low IMC–high
boostb (1991–2004)
697 7 303 11 2.59 (0.96–6.97) 0.060
aRadiation of IMC concerned 80% of patients during 1980–1990 and
declined to 15% during 1980–1987 and increased to 16 Gy during
1991–2004; boost dose was 10 Gy during 1988–2004.
bAdjusted for age, size, grade, and surgery.
cAdjusted for age only.
IMC, internal mammary chain; CI, confidence interval.
Table 4. Risk of cardiovascular mortality linked to quadrant in right-
and left-sided breast cancer
Laterality Quadrant Riska (95% CI) P value
Outer Inner
N Deaths N Deaths
Right 399 7 166 9 2.51 (0.88–7.18) 0.087
Left 452 5 227 7 2.17 (0.65–7.25) 0.208
aHazard ratios adjusted for age, tumor size, grade type of surgery and
period for inner versus outer breast quadrant; only death from
cardiovascular disease is considered.
CI, confidence interval.
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this study is based on cancer registry data not including
information on type and dose of radiotherapy treatment or
use of computed tomography simulation for evaluation of
doses to critical organs. This is the main limitation of our
study.
One can postulate that this excess of mortality linked to inner-
quadrant location is related to more frequent radiation of the
inner mammary lymph node chain. Irradiation of the IMC has
been associated with a more than twofold increased risk of
cardiovascular disease whatever the breast cancer laterality [9].
We observed no association between radiotherapy of inner-
quadrant breast cancer and cardiovascular mortality for the first
period when IMC was irradiated. This association was observed
only after 1988, when fewer patients underwent IMC radiation.
On the other hand, for the same period, the intensity of the boost
importantly increased from 10 to 16 Gy. Also, available data on
radiotherapy collected among patients who died of
cardiovascular disease show that patients with tumors of the
inner quadrants had more often higher boost to the breast and
higher dose of breast irradiation than patients with tumors of the
outer quadrants. Local recurrence occurred in only one patient
with right-sided outer-quadrant breast cancer and who
underwent additional surgery and radiation to the breast.
However, these findings could not be extrapolated to the
overall population of irradiated patients and we cannot
conclude that boost radiation is at the origin of the excess of
cardiovascular risk among patients with inner-quadrant breast
cancer.
In our study, the quadrant effect was similar for right- and
left-sided breast cancer. Our hypothesis is that boost
contributed to the excess of cardiovascular mortality. While
this is understandable for left-sided breast cancer, it is not
obvious for right-sided tumors, unless the boost fields are
extended toward the sternum. Future studies should investigate
this further, giving detailed information on radiation
treatment.
This study has also inherent limitations due to its
observational nature. In theory, no bias exists in the
distribution of patient and tumor characteristics according to
breast cancer laterality and quadrant. We therefore expected
a similar distribution of these variables among patients with
left- and right-sided breast cancer or with inner and outer
quadrants. We observed that patients with right-sided breast
cancer had more often ER-positive tumors, a finding we could
not explain. Finally, because of its short follow-up, we cannot
definitively rule out a lack of increase in cardiovascular
mortality linked to irradiation of the left breast.
This study also reports that tumor location in the inner
quadrants is associated with an increased risk of breast cancer-
specific mortality. The poorer prognosis of inner-quadrant
cancer has been previously reported and largely discussed [15–
18]. Patients with tumors of the inner quadrants are probably
more prone to have undetected metastases in the IMC. This
understaging results in undertreatment with higher breast
cancer-specific mortality as a consequence [18].
With regards to laterality, we found no excess risk of
cardiovascular mortality among irradiated patients with left-
sided breast cancer compared with patients presenting with
right-sided tumors.
Adjustments in the beam setup or in field shielding to avoid
radiation exposure to the heart during irradiation of left-sided
breast cancer has importantly decreased heart irradiation [14]
and is probably at the origin of more recent negative reports on
the association between laterality and cardiovascular risk [5–9,
Table 6. Type and dose of radiation therapy and cancer recurrence treatment according to laterality and tumor location among irradiated breast cancer
patients who died of cardiovascular disease
Laterality P value Quadrant P value
Right mean (SE) Left mean (SE) Outer mean (SE) Inner mean (SE)
No. of patients (N) 16 12 12 16
Delay between BC and
death (days)
2431.7 (353.7) 3258.0 (651.6) 0.245 2645.0 (525.1) 2891.4 (474.0) 0.732
Age (years) 71.5 (2.5) 67.7 (2.3) 0.289 71.0 (1.9) 69.0 (2.7) 0.583
Breast-conserving surgery 12 7 0.60 7 12 0.60
Total dose received (Gy) 52.4 (2.4) 55.7 (2.2) 0.37 48.9 (1.4) 56.4 (2.3) 0.03
Dose to the breast (Gy) 48.5 (0.7) 49.4 (0.7) 0.41 47.5 (1.0) 49.6 (0.4) 0.04
Boost (N) 3 4 0.66 1 6 0.18
Dose of the boost (Gy) 15.7 (0.3) 11.0 (1.0) 0.01 10.0 13.5 (1.2) 0.30
Mastectomy 2 3 0.71 3 2 0.71
Total dose received (Gy) 52.3 (7.3) 56.5 (3.6) 0.59 54.5 (4.8) 55.3 (5.8) 0.93
Dose to the chest wall (Gy) 47.3 (2.3) 47.5 (1.0) 0.91 47.2 (1.3) 47.8 (1.8) 0.80
SE, standard error; BC, Breast cancer diagnosis.
Table 5. Risk of cardiovascular mortality linked to laterality in outer-
and inner-quadrant breast cancer
Quadrant Laterality Riska (95% CI) P value
Right Left
N Deaths N Deaths
Outer 399 7 452 5 0.70 (0.21–2.32) 0.555
Inner 166 9 227 7 0.52 (0.18–1.48) 0.221
aHazard ratios adjusted for age, tumor size, grade type of surgery, and
period for inner versus outer breast quadrant; only death from
cardiovascular disease is considered.
CI, confidence interval.
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19–22]. However, several recent studies still report higher
cardiovascular mortality in patients with left-sided breast
cancer [23–26]. Also, the follow-up of our study is relatively
short compared with most previous studies, which reported an
excess of cardiovascular mortality linked to laterality after 10
years. Our data do not allow us to conclude that irradiation of
left-sided breast cancer has no more effect on cardiovascular
mortality.
We conclude that women irradiated for tumors of the inner
quadrants have an important increased risk of cardiovascular
mortality, probably linked to higher radiation exposure to the
heart due to the site of the boost. If our results are confirmed,
this adverse effect should be taken into account with the
expected benefits of such irradiation. Like for left-sided breast
cancer, adequate cardiac protection should be provided for
radiation therapy for inner-quadrant breast cancer.
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